Phase [II] clinical study of R435 (bevacizumab) in combination with paclitaxel in patients with inoperable metastatic breast cancer.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 25 Apr 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 25 Apr 2012 Actual patients number is 122 as reported by ClinicalTrials.gov.
- 25 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.